The Klinique Med Clinic PCL vs Delivery Hero: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

The Klinique Med Clinic PCL (KLINIQ.BK)

Q3 202624 Jul – 6 Oct 2026

▲3

KLINIQ raises 2026 target after strong H1, brokers see more upside

Company raises 2026 revenue target to 4.5 billion baht KLINIQ lifted its 2026 revenue goal to 4.5 billion baht from 4.15 billion after first-half revenue jumped 33% to 2.21 billion baht and profit rose 33%. Same-store sales grew 21.5%, showing existing clinics are busier, not just new ones. This directly boosts expected earnings and supports a higher share price.
This is the core new event that resets growth expectations for the year.
Brokers raise targets and flag record Q3 profit DAOL and Asia Plus both rate KLINIQ a Buy with targets of 34–35 baht, up from earlier levels. DAOL expects record third-quarter profit of 125–130 million baht and full-year profit up 31% to 476 million baht, driven by 10 new branches and double-digit same-store sales growth. Higher targets pull the share price up.
Analyst upgrades and record profit forecasts are a direct new catalyst for the stock.
Interim dividend of 0.80 baht and high yield attract income buyers KLINIQ is expected to pay an interim dividend of 0.80 baht per share, up 14% from last year, with a full-year yield as high as 5.6%. A steady, rising dividend makes the stock appealing to investors seeking income, which supports demand for the shares.
Dividend news is a new, concrete return of cash to shareholders that supports the price.
Global market jitters make KLINIQ a defensive pick, but risks remain Asia Plus warned of global pressures—oil at $91, rising US bond yields, and a record Thai current-account deficit—and named KLINIQ a safe-haven high-dividend stock. That defensive demand helps, but broad market weakness and foreign selling can still drag the price.
It shows the main counterweight: KLINIQ benefits as a defensive name but is not immune to market-wide selling.

August 202624 Jul – 6 Oct 2026

▲3

KLINIQ raises 2026 target after strong H1, brokers see more upside

Company raises 2026 revenue target to 4.5 billion baht KLINIQ lifted its 2026 revenue goal to 4.5 billion baht from 4.15 billion after first-half revenue jumped 33% to 2.21 billion baht and profit rose 33%. Same-store sales grew 21.5%, showing existing clinics are busier, not just new ones. This directly boosts expected earnings and supports a higher share price.
This is the core new event that resets growth expectations for the year.
Brokers raise targets and flag record Q3 profit DAOL and Asia Plus both rate KLINIQ a Buy with targets of 34–35 baht, up from earlier levels. DAOL expects record third-quarter profit of 125–130 million baht and full-year profit up 31% to 476 million baht, driven by 10 new branches and double-digit same-store sales growth. Higher targets pull the share price up.
Analyst upgrades and record profit forecasts are a direct new catalyst for the stock.
Interim dividend of 0.80 baht and high yield attract income buyers KLINIQ is expected to pay an interim dividend of 0.80 baht per share, up 14% from last year, with a full-year yield as high as 5.6%. A steady, rising dividend makes the stock appealing to investors seeking income, which supports demand for the shares.
Dividend news is a new, concrete return of cash to shareholders that supports the price.
Global market jitters make KLINIQ a defensive pick, but risks remain Asia Plus warned of global pressures—oil at $91, rising US bond yields, and a record Thai current-account deficit—and named KLINIQ a safe-haven high-dividend stock. That defensive demand helps, but broad market weakness and foreign selling can still drag the price.
It shows the main counterweight: KLINIQ benefits as a defensive name but is not immune to market-wide selling.

Latest24 Jul – 6 Oct 2026

▲3

KLINIQ raises 2026 target after strong H1, brokers see more upside

Company raises 2026 revenue target to 4.5 billion baht KLINIQ lifted its 2026 revenue goal to 4.5 billion baht from 4.15 billion after first-half revenue jumped 33% to 2.21 billion baht and profit rose 33%. Same-store sales grew 21.5%, showing existing clinics are busier, not just new ones. This directly boosts expected earnings and supports a higher share price.
This is the core new event that resets growth expectations for the year.
Brokers raise targets and flag record Q3 profit DAOL and Asia Plus both rate KLINIQ a Buy with targets of 34–35 baht, up from earlier levels. DAOL expects record third-quarter profit of 125–130 million baht and full-year profit up 31% to 476 million baht, driven by 10 new branches and double-digit same-store sales growth. Higher targets pull the share price up.
Analyst upgrades and record profit forecasts are a direct new catalyst for the stock.
Interim dividend of 0.80 baht and high yield attract income buyers KLINIQ is expected to pay an interim dividend of 0.80 baht per share, up 14% from last year, with a full-year yield as high as 5.6%. A steady, rising dividend makes the stock appealing to investors seeking income, which supports demand for the shares.
Dividend news is a new, concrete return of cash to shareholders that supports the price.
Global market jitters make KLINIQ a defensive pick, but risks remain Asia Plus warned of global pressures—oil at $91, rising US bond yields, and a record Thai current-account deficit—and named KLINIQ a safe-haven high-dividend stock. That defensive demand helps, but broad market weakness and foreign selling can still drag the price.
It shows the main counterweight: KLINIQ benefits as a defensive name but is not immune to market-wide selling.

Delivery Hero SE (DHER.XETRA)

Q3 20265 Jul – 24 Sep 2026

▲3

Uber's €12.7bn takeover bid drives Delivery Hero's Q3

Uber takeover offer Uber agreed to buy Delivery Hero for €41.50 per share, a 108% premium. It secured 53% via Prosus and launched a tender offer. Delivery Hero's boards recommended acceptance, and CEO Niklas Ostberg stayed to steer completion.
The takeover bid is the dominant new event that drove the stock.
Uber paused European expansion Uber paused its European expansion to ease antitrust concerns, a move that helped pave the way for the deal and reduced regulatory hurdles.
This regulatory concession was a key step enabling the takeover.
Raised guidance and strong H1 Delivery Hero raised its 2026 guidance, with H1 EBITDA beating expectations, showing underlying business strength amid the takeover.
Improved financial performance supports the company's value and deal rationale.
Deal completion risk The stock trades near the offer price, limiting upside and making returns dependent on deal completion. Regulatory approvals remain a condition, and SSW Partners' purchase of European units aims to address antitrust issues, highlighting execution risk.
This counterweight shows the main risk that could affect the stock if the deal falls through.

August 20265 Aug – 24 Sep 2026

▲4

Uber's €41.50 takeover offer advances, boards back deal

Uber's formal €41.50 offer gives shareholders a 108% premium Uber published its formal takeover offer on August 27, letting Delivery Hero shareholders tender shares for €41.50 cash each — about 108% above the price before the deal news. That high, fixed cash price is the main reason the stock trades near the offer level, since investors expect to receive that amount.
The formal offer sets the concrete cash price that anchors DHER's share price.
Delivery Hero boards recommend accepting Uber's offer On September 2, Delivery Hero's management and supervisory boards formally urged shareholders to accept Uber's roughly $15 billion bid, and top shareholder Prosus committed to tender its 17% stake. Board backing and a major shareholder locked in make completion more likely, supporting the shares.
Board and major-shareholder support materially raise the odds the deal closes at €41.50.
Delivery Hero raises 2026 guidance ahead of the offer Alongside the offer launch, Delivery Hero lifted its 2026 outlook, now expecting gross merchandise value to grow 9%–11%, and reported first-half adjusted EBITDA of €427 million, beating the €396 million analysts expected. Stronger underlying results make the company look healthier and support the deal case.
Improved guidance and earnings show the business is performing well, reinforcing the takeover value.
CEO Niklas Ostberg stays on to steer the Uber and SSW deals Delivery Hero said co-founder and CEO Niklas Ostberg will remain in charge through the Uber and SSW transactions. Keeping the founder-CEO provides continuity while the takeover is completed, reducing execution risk and reassuring investors that the deal process stays on track.
Leadership continuity during the takeover lowers execution risk and supports the shares.

Latest5 Aug – 24 Sep 2026

▲4

Uber's €41.50 takeover offer advances, boards back deal

Uber's formal €41.50 offer gives shareholders a 108% premium Uber published its formal takeover offer on August 27, letting Delivery Hero shareholders tender shares for €41.50 cash each — about 108% above the price before the deal news. That high, fixed cash price is the main reason the stock trades near the offer level, since investors expect to receive that amount.
The formal offer sets the concrete cash price that anchors DHER's share price.
Delivery Hero boards recommend accepting Uber's offer On September 2, Delivery Hero's management and supervisory boards formally urged shareholders to accept Uber's roughly $15 billion bid, and top shareholder Prosus committed to tender its 17% stake. Board backing and a major shareholder locked in make completion more likely, supporting the shares.
Board and major-shareholder support materially raise the odds the deal closes at €41.50.
Delivery Hero raises 2026 guidance ahead of the offer Alongside the offer launch, Delivery Hero lifted its 2026 outlook, now expecting gross merchandise value to grow 9%–11%, and reported first-half adjusted EBITDA of €427 million, beating the €396 million analysts expected. Stronger underlying results make the company look healthier and support the deal case.
Improved guidance and earnings show the business is performing well, reinforcing the takeover value.
CEO Niklas Ostberg stays on to steer the Uber and SSW deals Delivery Hero said co-founder and CEO Niklas Ostberg will remain in charge through the Uber and SSW transactions. Keeping the founder-CEO provides continuity while the takeover is completed, reducing execution risk and reassuring investors that the deal process stays on track.
Leadership continuity during the takeover lowers execution risk and supports the shares.

July 20265 Jul – 25 Jul 2026

▲4

Uber's €12.7bn takeover of Delivery Hero becomes a done deal

Uber pauses Europe expansion to smooth takeover path Uber shelved most of its planned Uber Eats launches in Europe, a move seen as reducing antitrust hurdles for its Delivery Hero bid. This raised hopes of a successful deal, supporting DHER shares.
Shows a concrete step by Uber to clear regulatory obstacles, increasing deal certainty.
Uber and Delivery Hero confirm advanced takeover talks Delivery Hero confirmed it was in advanced negotiations with Uber, with a deal likely valuing it above €36 per share. This official confirmation made the takeover highly probable, pushing the stock up.
Directly signals a near-term acquisition at a premium, a major price catalyst.
Uber agrees to buy Delivery Hero for €12.7 billion Uber announced a €41.50 per share offer, a premium to recent prices, with SSW Partners buying some European units to ease regulatory concerns. The deal locks in a high exit price for shareholders.
The actual deal announcement sets a firm floor and upside for DHER shares.
Uber launches tender offer after securing 53% stake Uber reached 53% ownership via a purchase from Prosus and launched a voluntary tender offer for remaining shares. This confirms the deal's progress and gives minority holders a clear path to sell at the offer price.
Shows the acquisition is advancing, reducing uncertainty for remaining shareholders.

5 Jul – 25 Jul 2026

▲4

Uber's €12.7bn takeover of Delivery Hero becomes a done deal

Uber pauses Europe expansion to smooth takeover path Uber shelved most of its planned Uber Eats launches in Europe, a move seen as reducing antitrust hurdles for its Delivery Hero bid. This raised hopes of a successful deal, supporting DHER shares.
Shows a concrete step by Uber to clear regulatory obstacles, increasing deal certainty.
Uber and Delivery Hero confirm advanced takeover talks Delivery Hero confirmed it was in advanced negotiations with Uber, with a deal likely valuing it above €36 per share. This official confirmation made the takeover highly probable, pushing the stock up.
Directly signals a near-term acquisition at a premium, a major price catalyst.
Uber agrees to buy Delivery Hero for €12.7 billion Uber announced a €41.50 per share offer, a premium to recent prices, with SSW Partners buying some European units to ease regulatory concerns. The deal locks in a high exit price for shareholders.
The actual deal announcement sets a firm floor and upside for DHER shares.
Uber launches tender offer after securing 53% stake Uber reached 53% ownership via a purchase from Prosus and launched a voluntary tender offer for remaining shares. This confirms the deal's progress and gives minority holders a clear path to sell at the offer price.
Shows the acquisition is advancing, reducing uncertainty for remaining shareholders.